Skip to main content

Allyson Wilkinson

Associate

[email protected]

+1.617.348.4456

Share:

Allyson leverages her in-house experience to provide holistic counsel to publicly traded and late-stage private companies on corporate and securities law matters.

 

Allyson advises companies on SEC reporting and disclosure requirements, corporate governance, stock exchange requirements and proxy advisory firm policies. Allyson routinely represents issuers on a variety of transactions, with a focus on initial public offerings, follow-on offerings, private investments in public equity (PIPEs), registered direct offerings and mergers and acquisitions.

 

Before rejoining Mintz, Allyson was Senior Counsel, Corporate and Securities at a prominent tech company in New York, where she advised the board and senior management on a wide range of corporate and securities law matters.

Experience

Select Initial Public Offering Representations

  • Viela Bio, Inc. in its $150 million initial public offering.
  • NuCana plc. in its $114 million initial public offering. 
  • Quanterix Corporation in its $73.7 million initial public offering.

Select Follow-on Offering and Alternate Transaction Representations

  • Intra-Cellular Therapies, Inc. in multiple offerings, including its $350 million follow-on offering, its $295 million follow-on offering, and its $150 million follow-on offering. 
  • Albireo Pharma, Inc. in multiple offerings, including its $160 million follow-on offering and its $65 million follow-on offering. 
  • Viela Bio, Inc. in multiple offerings, including its $170 million follow-on offering. 
  • Nucana plc. in multiple offerings, including its $70 million follow-on offering.
  • J.P. Morgan, SVB Leerink, and Cowen in Acceleron Pharma Inc.’s $493 million follow-on offering.
  • Goldman Sachs, Morgan Stanley, J.P. Morgan, and Cowen in GW Pharmaceuticals plc.’s $345 million follow-on offering.
  • Goldman Sachs and Leerink Partners in a $50.5 million secondary offering of Achillion Pharmaceuticals, Inc.’s common stock by selling stockholder Johnson & Johnson Innovation-JJDC, Inc.
  • Leerink Partners in ArQule, Inc.’s $65 million follow-on offering.

Select Mergers and Acquisitions Representations

  • Albireo Pharma, Inc. in its reverse merger with Biodel Inc.
  • F-star Therapeutics, Inc. in its reverse merger with Spring Bank Pharmaceuticals.
Read less

News & Press

Press Release Thumbnail
Firm plays a key role in the largest health care acquisition to date in 2020.
Mintz represents NuCana, which completed its approximately $114 million initial public offering. The United Kingdom-based clinical-stage company focuses on improving treatment outcomes for patients with cancer.
Read less

Events & Speaking

Speaker
Nov
20
2019

Recent SEC Rulemaking

Boston Bar Association

Read less

Recognition & Awards

  • Richard Mintz Scholarship Recipient

  • Boston College Law School’s Pro Bono Excellence Recognition

  • National Black Lawyers: Top 40 Under 40 (2022)

  • Massachusetts Lawyers Weekly: Excellence in the Law, Up & Coming Lawyer Award (2020)

Read less

Involvement

  • Director, The Equity in Heart Transplant Project (2022 – present)
  • Clerk, The Equity in Heart Transplant Project (2022 – 2023)
  • Treasurer, Massachusetts Black Lawyers Association (2022 – 2023)
  • Business Transactions Liaison, New Lawyers Steering Committee of the Boston Bar Association (2020 – 2021)
  • Director, Boston College Law School Black Alumni Network (2019 – 2020)
Read less